[Heart arrhythmias and congestive heart failure].
Along with the successful pharmacotherapic achievements in patients with congestive heart failure survival rate in this category of patients still remains unfavourable. Many antiarrhythmic drugs that cause proarrhythmic effect in patients with congestive heart failure, are characterized by narrow therapeutic window of action and their metabolism is usually changed. Patients with ventricular arrhythmias and disturbances of left ventricular function belong to group with elevated risk of sudden death and complex ventricular impairments are predictors of lethal outcome. Use of ACE inhibitors, angiotensin II receptor inhibitors, beta-blockers (in order to control ventricular rhythm during tachycardia) in combination with antiarrythmic drugs increases effectiveness and safety of therapy, lowers degree of congestive heart failure development and improves prognosis of diseases of that kind. Utilization of nonarrhythmic drugs during treatment of arrhythmias including atrial fibrillation, is novel approach in the treatment with antiarhythmic drugs.
Abuladze
G V
GV
Narciia
E V
EV
Mamamtavrishvili
N D
ND
Nikolaishvili
M G
MG
Kantariia
D A
DA
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans
D000889:Anti-Arrhythmia Agents